Progenics Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Progenics Pharmaceuticals, Inc.
Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
- Digital Health
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
- Diagnostic Imaging Equipment & Supplies
Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Molecular Insight Pharmaceuticals, Inc.
- PSMA Development Company
- UR Labs (URL)